Skip to main content
Top
Published in: Current Gastroenterology Reports 6/2024

17-04-2024 | Constipation

Capsules for the Diagnosis and Treatment of Gastrointestinal Motility Disorders- A Game Changer

Authors: Irene Sonu, Sun Jung Oh, Satish S. C. Rao

Published in: Current Gastroenterology Reports | Issue 6/2024

Login to get access

Abstract

Purpose of Review

Over the last few decades, there have been remarkable strides in endoscopy and radiological imaging that have advanced gastroenterology. However, the management of neurogastroenterological disorders has lagged behind, in part handicapped by the use of catheter-based manometry that is both non-physiological and uncomfortable. The advent of capsule technology has been a game changer for both diagnostic and therapeutic applications.

Recent Findings

Here, we discuss several capsule devices that are available or under investigation. There are three technologies that are FDA approved. Wireless motility capsule measures pH and pressure and provides clinically impactful information regarding gastric, small intestine and colonic transit, without radiation that has been demonstrated to guide management of gastroparesis, dyspepsia and constipation. Wireless ambulatory pH monitoring capsule is currently the gold standard for assessing gastroesophageal acid reflux. In the therapeutics arena, an orally ingested vibrating capsule has been recently FDA approved for the treatment of chronic constipation, supported by a robust phase 3 clinical trial which showed significant improvement in constipation symptoms and quality of life. There are several capsules currently under investigation. Smart capsule bacterial detection system and Capscan® are capsules that can sample fluid in the small or large bowel and provide microbiome analysis for detection of small intestinal bacterial (SIBO) or fungal overgrowth (SIFO). Another investigational gas sensing capsule analyzing hydrogen, CO2, volatile fatty acids and capsule orientation, can measure regional gut transit time and luminal gas concentrations and assess gastroparesis, constipation or SIBO. Therapeutically, other vibrating capsules are in development.

Summary

Innovations in capsule technology are poised to transform our ability to investigate gut function physiologically, and non-invasively deliver targeted treatment(s), thereby providing both accurate diagnostic information and luminally-directed, safe therapy.
Literature
1.
go back to reference •• Rao SSC, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011;23(1):8–23. https://doi.org/10.1111/j.1365-2982.2010.01612.x. The American and European Neurogastroenterology and Motility Societies published guidelines on the methods of assessing transit including indications for use of the wireless capsule motility capsule. This overview provides background on the performance characteristics, clinical indications, strengths and weaknesses of the wireless motility capsule in comparison to traditional diagnostics such as scintigraphy and radio-opaque marker studies. •• Rao SSC, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011;23(1):8–23. https://​doi.​org/​10.​1111/​j.​1365-2982.​2010.​01612.​x. The American and European Neurogastroenterology and Motility Societies published guidelines on the methods of assessing transit including indications for use of the wireless capsule motility capsule. This overview provides background on the performance characteristics, clinical indications, strengths and weaknesses of the wireless motility capsule in comparison to traditional diagnostics such as scintigraphy and radio-opaque marker studies.
6.
go back to reference •• Rao SSC, Quigley EMM, Chey WD, et al. Randomized placebocontrolled phase 3 trial of vibrating capsule for chronic constipation. Gastroenterology. 2023;164(7):1202–10.E6. https://doi.org/10.1053/j.gastro.2023.02.013. This phase 3 randomizedcontrolled trial showed that vibrating capsule, a first, nonpharmacological, therapeutic option for treatment of constipation, was safe and effective, and superior to sham capsule and improved bowel symptoms, stool characteristics and quality of life. •• Rao SSC, Quigley EMM, Chey WD, et al. Randomized placebocontrolled phase 3 trial of vibrating capsule for chronic constipation. Gastroenterology. 2023;164(7):1202–10.E6. https://​doi.​org/​10.​1053/​j.​gastro.​2023.​02.​013. This phase 3 randomizedcontrolled trial showed that vibrating capsule, a first, nonpharmacological, therapeutic option for treatment of constipation, was safe and effective, and superior to sham capsule and improved bowel symptoms, stool characteristics and quality of life.
17.
go back to reference •• Wenner J, Johnsson F, Johansson J, et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102(2):239–45. https://doi.org/10.1111/j.1572-0241.2006.00939.x. This randomized cross-over trial illustrated that wireless pH monitoring resulted in less interference in daily activities, more normal daily oral intake and less adverse symptoms, thus is preferred over catheter-based monitoring. •• Wenner J, Johnsson F, Johansson J, et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102(2):239–45. https://​doi.​org/​10.​1111/​j.​1572-0241.​2006.​00939.​x. This randomized cross-over trial illustrated that wireless pH monitoring resulted in less interference in daily activities, more normal daily oral intake and less adverse symptoms, thus is preferred over catheter-based monitoring.
22.
go back to reference Lee SN, Stork C, Smith J, et al. Development of ex-vivo and in vivo models to assess the performance of an oral biotherapeutic delivery system (OBDS) device. Poster Presented at: Controlled Release Society Annual Meeting, July 13–14, 2022, Montreal, Canada. Lee SN, Stork C, Smith J, et al. Development of ex-vivo and in vivo models to assess the performance of an oral biotherapeutic delivery system (OBDS) device. Poster Presented at: Controlled Release Society Annual Meeting, July 13–14, 2022, Montreal, Canada.
23.
go back to reference Lee SN, Sandefer E, Stork C, et al. A scintigraphic study to evaluate the safety, tolerability, and functions of a drug delivery system (DDS) device in healthy subjects in fasted state. Am J Gastroenterol. 2022;117(10S):e766–7. Lee SN, Sandefer E, Stork C, et al. A scintigraphic study to evaluate the safety, tolerability, and functions of a drug delivery system (DDS) device in healthy subjects in fasted state. Am J Gastroenterol. 2022;117(10S):e766–7.
Metadata
Title
Capsules for the Diagnosis and Treatment of Gastrointestinal Motility Disorders- A Game Changer
Authors
Irene Sonu
Sun Jung Oh
Satish S. C. Rao
Publication date
17-04-2024
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 6/2024
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-024-00926-8
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.